Pharmacyclics close to new highs after Lazard upgrade

|By:, SA News Editor

Shares of Pharmacyclics (PCYC +1.4%) are trading around their 52-week (and all-time) highs.

Helping the cause is Lazard, where analysts upgraded the shares to Buy from Neutral earlier today.

Recently: FDA accepts ibrutinib NDA for two B-cell malignancy indications.